TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Evaluate the Role of Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan
Brief Summary: Routine childhood immunization (RCI) in Pakistan is well below the recommended coverage of 90% with rates as low as 16% in certain regions (Pakistan DHS 2012-3). This has led to continued polio transmission, large measles outbreaks and thousands of deaths from vaccine-preventable diseases (Kazi.Bull WHO 2016). Mobile phone communication is widespread in developing countries and has proven a potential method of directly connecting pregnant women and mothers to health services (Kharbanda. Expert Review of Vaccine 2014). The investigators propose conducting a mixed methods proof of concept cluster randomized trial (CRT) to assess the effectiveness of different types of SMS messaging and automated calls to improve RCI and understand the perceptions and barriers that may affect SMS and automated call-based interventions at participants levels. the investigators will conduct the study at urban and rural sites in Pakistan. The investigators will examine an important public health question - do low cost, automated SMS, and automated messages improve RCI coverage in resource-constrained settings? Further, investigators will compare the effectiveness of reminder, educational and interactive text messages for improving RCI and will generate socio-cultural data regarding the impact of participants health beliefs that will be important for setting up the appropriate interventions in other LMICs.


Options:
A: Arm Label: Standard of Care (SoC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SoC + iTab; Type: ACTIVE_COMPARATOR; Interventions: Device: SoC + iTab | Intervention Type: DEVICE; Name: SoC + iTab; Assigned to Arm(s): SoC + iTab
B: Arm Label: mHealth; Type: EXPERIMENTAL; Interventions: Other: mHealth | Arm Label: No mHealth; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: mHealth; Assigned to Arm(s): mHealth
C: Arm Label: 1. One way SMS messages.; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS messages and automated calls | Arm Label: 2. Two Way SMS messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS messages and automated calls | Arm Label: 3. One way automated calls.; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS messages and automated calls | Arm Label: 4.Two way interactive automated calls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS messages and automated calls | Arm Label: 5. Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS messages and automated calls; Assigned to Arm(s): 1. One way SMS messages., 2. Two Way SMS messages, 3. One way automated calls., 4.Two way interactive automated calls
D: Arm Label: health education; Type: EXPERIMENTAL; Interventions: Other: health education | Arm Label: no health education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): health education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Developing, Implementing and Evaluating Preschool Based Interventions to Address Family Violence and Alcohol and Drug Misuse in Sri Lanka
Brief Summary: The investigators aim to implement a community-based support program delivered by preschool teachers and volunteer parents that will increase awareness, knowledge and uptake of available services for IPV and substance misuse, and of the link between these issues and poorer education outcomes in children. Through this, the aim is to decrease the prevalence of IPV and substance misuse.

The proposed method of implementation is to deliver targeted training to preschool teachers, mothers with children at the preschools, fathers with children at the preschools, and community development officers managing preschools. This project will target the most vulnerable sections of the community and will provide a sustainable and feasible strategy for scale up of the intervention.

By intervening through these preschools the investigators aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.


Options:
A: Arm Label: Mothers and Babies Groups Home-Visitor; Type: EXPERIMENTAL; Interventions: Behavioral: Mothers and Babies Groups | Arm Label: Mothers and Babies Groups Clinician; Type: EXPERIMENTAL; Interventions: Behavioral: Mothers and Babies Groups | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mothers and Babies Groups; Assigned to Arm(s): Mothers and Babies Groups Clinician, Mothers and Babies Groups Home-Visitor
B: Arm Label: Family Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family intervention; Assigned to Arm(s): Family Intervention
C: Arm Label: Maternal support to become mother; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal support to become mother | Arm Label: Control group: usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group: usual care | Intervention Type: BEHAVIORAL; Name: Maternal support to become mother; Assigned to Arm(s): Maternal support to become mother | Intervention Type: BEHAVIORAL; Name: Control Group: usual care; Assigned to Arm(s): Control group: usual Care
D: Arm Label: Intervention preschools; Type: OTHER; Interventions: Behavioral: Capacity building to support families affected by IPV & substance misuse | Arm Label: Control preschool; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Capacity building to support families affected by IPV & substance misuse; Assigned to Arm(s): Intervention preschools

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Brief Summary: This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.


Options:
A: Arm Label: single arm; Type: EXPERIMENTAL; Interventions: Biological: CD19-targeted CAR-T cells | Intervention Type: BIOLOGICAL; Name: CD19-targeted CAR-T cells; Assigned to Arm(s): single arm
B: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab
C: Arm Label: JWCAR029; Type: EXPERIMENTAL; Interventions: Biological: JWCAR029 | Intervention Type: BIOLOGICAL; Name: JWCAR029; Assigned to Arm(s): JWCAR029
D: Arm Label: AUTO3; Type: EXPERIMENTAL; Interventions: Biological: AUTO3 | Intervention Type: BIOLOGICAL; Name: AUTO3; Assigned to Arm(s): AUTO3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The What and How in Weaning: A Randomized Controlled Trial to Assess the Effects of Vegetable-exposure and Responsive Feeding on Vegetable Acceptance in Infants and Toddlers
Brief Summary: Overweight and obesity in preschool children is more and more common and predicts overweight in later childhood and adulthood. A healthy eating pattern with many vegetables decreases the risk to develop overweight. As many food preferences are learned in the first years of life, teaching children to like vegetables from the very start of eating solid foods is essential. Starting baby's first bites of solid foods with vegetables instead of more sweet tastes like fruits may promote vegetable liking. Also, it is important that parents know how to feed their children: e.g., paying attention to whether the child is hungry or full is essential, as is not pressuring them to eat. What is yet unknown is which of these two are more important to promote, to facilitate vegetable liking in young children. Is starting with vegetables most important, or educating parents on their feeding-techniques? And is a combination of both most effective? This study tests which of three interventions is most effective to promote vegetable intake and liking in children up until the age of 3 years: a) a focus on the 'what' (starting with vegetables); b) a focus on the 'how' (listen to your child's cues while feeding); c) a focus on both the 'what' and the 'how'. These three groups will be compared to a control group receiving no advice on how to introduce solid foods on children's vegetable intake and liking.


Options:
A: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
B: Arm Label: Vegetable exposure; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure | Arm Label: VIPP-Feeding Infants; Type: EXPERIMENTAL; Interventions: Behavioral: VIPP-Feeding Infants | Arm Label: Exposure + VIPP-FI; Type: EXPERIMENTAL; Interventions: Other: Vegetable exposure, Behavioral: VIPP-Feeding Infants | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Vegetable exposure; Assigned to Arm(s): Exposure + VIPP-FI, Vegetable exposure | Intervention Type: BEHAVIORAL; Name: VIPP-Feeding Infants; Assigned to Arm(s): Exposure + VIPP-FI, VIPP-Feeding Infants | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: motivational counseling; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): motivational counseling
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Uncut Roux-en-Y vs Roux-en-Y Reconstruction After Distal Gastrectomy for Gastric Cancer
Brief Summary: Uncut Roux-en-Y vs Roux-en-Y reconstruction after distal gastrectomy for gastric cancer


Options:
A: Arm Label: Billroth-I; Type: EXPERIMENTAL; Interventions: Procedure: Billroth-I | Arm Label: Roux en Y; Type: EXPERIMENTAL; Interventions: Procedure: Roux en Y | Intervention Type: PROCEDURE; Name: Billroth-I; Assigned to Arm(s): Billroth-I | Intervention Type: PROCEDURE; Name: Roux en Y; Assigned to Arm(s): Roux en Y
B: Arm Label: Gastroduodenostomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Gastroduodenostomy | Arm Label: Roux-en Y gastrojejunostomy; Type: EXPERIMENTAL; Interventions: Procedure: Roux-en Y gastrojejunostomy | Intervention Type: PROCEDURE; Name: Roux-en Y gastrojejunostomy; Assigned to Arm(s): Roux-en Y gastrojejunostomy | Intervention Type: PROCEDURE; Name: Gastroduodenostomy; Assigned to Arm(s): Gastroduodenostomy
C: Arm Label: modified BII+Braun; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified BII+Braun | Arm Label: traditional BII+Braun; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: modified BII+Braun; Assigned to Arm(s): modified BII+Braun
D: Arm Label: the group of Roux-en-Y; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-en-Y reconstruction | Arm Label: the group of Uncut Roux-en-Y; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y reconstruction; Assigned to Arm(s): the group of Uncut Roux-en-Y | Intervention Type: PROCEDURE; Name: Roux-en-Y reconstruction; Assigned to Arm(s): the group of Roux-en-Y

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Deferred Versus Fresh Embryo Transfers in Infertile Women Undergoing IVF-ICSI
Brief Summary: Controlled ovarian stimulation (COS) enhances the efficacy of ART (Assisted reproductive technology) by permitting multiple-oocyte yields, but also alters endometrial receptivity (ER) by an advancement of endometrial development which contributes to diminished pregnancy chances. Previous reports suggest that pregnancy rates are increased following deferred frozen embryo transfers. In addition as compared to fresh embryo transfers, frozen embryo transfers seem to be associated with less affected perinatal outcomes, in particular lower risk of preterm birth, small for gestational age and caesarean section. Unfortunately, most of the current evidence is based only on preliminary reports, needing further scientific evidence. Thus, whether differing embryo transfers could restore optimal ER leading to higher live birth rate (LBR) and better obstetrical outcomes as compared to fresh embryo transfers, is actually still under investigation.


Options:
A: Arm Label: Fresh transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh transfer | Arm Label: Deferred-frozen embryo transfer; Type: EXPERIMENTAL; Interventions: Procedure: Deferred-frozen embryo transfer | Intervention Type: PROCEDURE; Name: fresh transfer; Assigned to Arm(s): Fresh transfer | Intervention Type: PROCEDURE; Name: Deferred-frozen embryo transfer; Assigned to Arm(s): Deferred-frozen embryo transfer
B: Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh embryo transfer | Arm Label: Intervention arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Frozen embryo transfer | Intervention Type: PROCEDURE; Name: Fresh embryo transfer; Assigned to Arm(s): Control arm | Intervention Type: PROCEDURE; Name: Frozen embryo transfer; Assigned to Arm(s): Intervention arm
C: Arm Label: freeze all embryos following PGD; Type: EXPERIMENTAL; Interventions: Procedure: elective cryopreservation of available embryos after PGD | Arm Label: elective fresh embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD | Intervention Type: PROCEDURE; Name: elective cryopreservation of available embryos after PGD; Assigned to Arm(s): freeze all embryos following PGD | Intervention Type: PROCEDURE; Name: PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD; Assigned to Arm(s): elective fresh embryo transfer
D: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Non-dialysis Subjects Previously Treated With Erythropoiesis-Stimulating Agents (ESAs)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)


Options:
A: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: Daprodustat receivers; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat (GSK1278863), Drug: Iron therapy | Arm Label: Placebo receivers; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat (GSK1278863); Assigned to Arm(s): Daprodustat receivers | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo receivers | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat receivers, Placebo receivers
C: Arm Label: Vadadustat, Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 3; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat, Dose 1, Vadadustat, Dose 2, Vadadustat, Dose 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)


Options:
A: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
B: Arm Label: GSK1278863; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Control; Type: OTHER; Interventions: Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Control
C: Arm Label: Daprodustat in ND participants; Type: EXPERIMENTAL; Interventions: Drug: 1 to 4 mg tablets of GSK1278863, Drug: 6 mg GSK1278863 tablet | Arm Label: Epoetin beta pegol in ND participants; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin beta pegol | Arm Label: Daprodustat in PD participants; Type: EXPERIMENTAL; Interventions: Drug: 1 to 4 mg tablets of GSK1278863, Drug: 6 mg GSK1278863 tablet | Intervention Type: DRUG; Name: 1 to 4 mg tablets of GSK1278863; Assigned to Arm(s): Daprodustat in ND participants, Daprodustat in PD participants | Intervention Type: DRUG; Name: 6 mg GSK1278863 tablet; Assigned to Arm(s): Daprodustat in ND participants, Daprodustat in PD participants | Intervention Type: DRUG; Name: Epoetin beta pegol; Assigned to Arm(s): Epoetin beta pegol in ND participants
D: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer
Brief Summary: Lung cancer is the most common cancer in the world and the leading cause of cancer-related deaths in Western countries. Unfortunately, at the time of diagnosis, the majority of patients already have metastatic disease and a systemic, palliative treatment is the primary therapeutic option.

Guidelines for PS 2 patients or older than 75 years old patients at the time of diagnosis recommend for fit patients a carboplatin doublet chemotherapy.

Nivolumab has proven efficacy in 3rd line squamous cell lung carcinoma and is superior to chemotherapy in 2nd line treatment of squamous and non-squamous lung cancer in term of overall survival.

In 1st line, nivolumab failed to show superiority compared to a platin based doublet in terms of progression free survival and overall survival in tumors ≥ 5% PD-L1 expression. The association Nivolumab plus Ipilimumab showed encouraging results in first line setting in phase 1 study.

The investigators think that with regard to the manageable toxicity of nivolumab in lung cancer population and the possibility to obtain long responses, this association could be a valid option for this population of elderly and/or PS2 patients in term of overall survival.


Options:
A: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: A